Literature DB >> 18207595

Dosimetric effects of the prone and supine positions on image guided localized prostate cancer radiotherapy.

Bei Liu1, Fritz A Lerma, Shilpen Patel, Pradip Amin, Yuanming Feng, Byong Yong Yi, Cedric Yu.   

Abstract

PURPOSE: To compare target coverage and doses to rectum and bladder in IMRT of localized prostate cancer in the supine versus prone position, with the inclusion of image guidance.
MATERIALS AND METHODS: Twenty patients with early stage localized prostate carcinoma who received external beam radiotherapy in the supine and prone positions underwent approximately 10 serial CT examinations in their respective treatment position in non-consecutive days, except for one patient who was treated prone but serially imaged supine. The prostate, bladder and rectum were contoured on all CT scans. A PTV was generated on the first scan of each patient's CT series by expanding the prostate with a 5mm margin and an IMRT plan was created. The resultant IMRT plan was then applied to that patient's remaining serial CT scans by aligning the initial CT image set with the subsequent serial CT image sets using (1) skin marks, (2) bony anatomy and (3) center of mass of the prostate. The dosimetric results from these three alignments were compared between the supine and prone groups. To account for the uncertainties associated with prostate delineation and intra-fractional geometric changes, a fictional "daily PTV" was generated by expanding the prostate with a 3mm margin on each serial CT scan. Thus, a more realistic target coverage index, V95, was quantified as the fraction of the daily PTV receiving at least 95% of the prescription dose. Dose-volume measures of the organs at risk were also compared. The fraction of the daily PTV contained by the initial PTV after each alignment method was quantified on each patient's serial CT scan, and is defined as PTV overlap index.
RESULTS: As expected, alignment based on skin marks yielded unacceptable dose coverage for both groups of patients. Under bony alignment, the target coverage index, V95, was 97.3% and 93.6% for prone and supine patients (p<0.0001), respectively. The mean PTV overlap indices were 90.7% and 84.7% for prone and supine patients (p<0.0002), respectively. In the supine position 36% of cases showed a V95<95% after bony alignment, while only 12.5% of prone patients with V95<95% following bony alignment. Under soft-tissue alignment matching the center of mass of the prostate, the mean V95 was 99.3% and 98.6% (p<0.03) and the PTV overlap index was 97.7% and 94.8% (p<0.0002) for prone and supine groups, respectively.
CONCLUSIONS: Soft-tissue alignment combined with 5mm planning margins is appropriate in minimizing treatment planning and delivery uncertainties in both the supine and prone positions. Alignment based on bony structures showed improved results over the use of skin marks for both supine and prone setups. Under bony alignment, the dose coverage and PTV overlap index for prone setup were statistically better than for supine setup, illustrating a more consistent geometric relationship between the prostate and the pelvic bony structures when patients were treated in the prone position.

Entities:  

Mesh:

Year:  2008        PMID: 18207595     DOI: 10.1016/j.radonc.2007.11.034

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  8 in total

1.  Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy.

Authors:  Jeffrey R Olsen; Parag J Parikh; Michael Watts; Camille E Noel; Kenneth W Baker; Lakshmi Santanam; Jeff M Michalski
Journal:  Radiother Oncol       Date:  2012-07-17       Impact factor: 6.280

2.  Patient positioning variations to reduce dose to normal tissues during 3D conformal radiotherapy for high-risk prostate cancer.

Authors:  K Czigner; P Agoston; G Forgács; M Kásler
Journal:  Strahlenther Onkol       Date:  2012-05-23       Impact factor: 3.621

Review 3.  ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2016-10-20

4.  Using daily diagnostic quality images to validate planning margins for prostate interfractional variations

Authors:  Wen Li; Andrew Vassil; Andrew Godley; Lama Muhieddine Mossolly; Qingyang Shang; Ping Xia
Journal:  J Appl Clin Med Phys       Date:  2016-05-08       Impact factor: 2.102

5.  Dosimetric effects of prone and supine positions on post-implant assessments for prostate brachytherapy.

Authors:  Toshio Ohashi; Tetsuo Momma; Shoji Yamashita; Kunimitsu Kanai; Yusuke Watanabe; Takashi Hanada; Naoyuki Shigematsu
Journal:  J Contemp Brachytherapy       Date:  2013-09-20

6.  Assessment of interfractional prostate motion in patients immobilized in the prone position using a thermoplastic shell.

Authors:  Itaru Ikeda; Takashi Mizowaki; Yohei Sawada; Manabu Nakata; Yoshiki Norihisa; Masakazu Ogura; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2013-07-16       Impact factor: 2.724

Review 7.  ACR Appropriateness Criteria for external beam radiation therapy treatment planning for clinically localized prostate cancer, part II of II.

Authors:  Nicholas G Zaorsky; Timothy N Showalter; Gary A Ezzell; Paul L Nguyen; Dean G Assimos; Anthony V D'Amico; Alexander R Gottschalk; Gary S Gustafson; Sameer R Keole; Stanley L Liauw; Shane Lloyd; Patrick W McLaughlin; Benjamin Movsas; Bradley R Prestidge; Al V Taira; Neha Vapiwala; Brian J Davis
Journal:  Adv Radiat Oncol       Date:  2017-03-20

8.  Intrafraction displacement of prone versus supine prostate positioning monitored by real-time electromagnetic tracking.

Authors:  Wayne M Butler; Gregory S Merrick; Joshua L Reed; Brian C Murray; Brian S Kurko
Journal:  J Appl Clin Med Phys       Date:  2013-03-04       Impact factor: 2.102

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.